Makers Laboratories

Makers Laboratories R&D per Employee

The R&D Spending per Employee of Makers Laboratories (506919.BO) as of Oct 16, 2026 is 24,380.17 INR. In the previous year, R&D Spending per Employee was 14,958.68 INR — a change of 62.98% (higher).

R&D per Employee

24,380.17INR

YoY

62.98%

Last updated:

R&D Spending per Employee of Makers Laboratories is 2026 24,380.17 INR. R&D Spending per Employee of Makers Laboratories was 2025 14,958.68 INR. It decreases by 62.98% higher compared to the previous year.

The Makers Laboratories R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
2,421.49 INR
Jan 1, 2020
2,264.46 INR
Jan 1, 2021
19,694.21 INR
Jan 1, 2022
43,561.98 INR
Jan 1, 2023
21,322.31 INR
Jan 1, 2024
10,520.66 INR
Jan 1, 2025
14,958.68 INR
Jan 1, 2026
24,380.17 INR
The Makers Laboratories R&D per Employee history
YEARR&D per EmployeeYoY
24,380.17INR+62.98%
14,958.68INR+42.18%
10,520.66INR-50.66%
21,322.31INR-51.05%
43,561.98INR+121.19%
19,694.21INR+769.71%
2,264.46INR-6.48%
2,421.49INR-34.89%
3,719.01INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd is a pharmaceutical company headquartered in Mumbai, India, operating within the Health Care sector. The company has a workforce of 121 employees and went public on July 13, 1993. It manufactures and markets pharmaceutical products, focusing on various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). Additionally, Makers Laboratories offers Inspira retail packs, covering categories like acid regulatory, anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics, anti-nauseants, anti-fungal, anti-hypertensives, and other health-related products. The Experia bulk packs division provides bulk pharmaceutical products including amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and similar items. The company's website is https://www.makerslabs.com/. Makers Laboratories Ltd is listed on the Bombay Stock Exchange under the ticker 506919.BO and holds the ISIN INE987A01010. The company operates through the pharmaceuticals segment, emphasizing general health therapeutic areas. It does not disclose specific financial figures or additional details beyond its product lines and operational structure. Makers Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Makers Laboratories stock

R&D Spending per Employee of Makers Laboratories is 24,380.17 INR in 2026.

R&D Spending per Employee of Makers Laboratories changed from 14,958.68 INR to 24,380.17 INR, representing a 62.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Makers Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Makers Laboratories

All Key Metrics — Makers Laboratories